These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31308029)

  • 1. ADAM10 Is a Potential Novel Prognostic Biomarker for Sacral Chordoma.
    Ding Y; Bui MM; Wang Q; Sun X; Zhang M; Niu X; Tian W
    Ann Clin Lab Sci; 2019 May; 49(3):309-316. PubMed ID: 31308029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis.
    Chen K; Mo J; Zhou M; Wang G; Wu G; Chen H; Zhang K; Yang H
    Med Oncol; 2014 Apr; 31(4):886. PubMed ID: 24535608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High expression of SPHK1 in sacral chordoma and association with patients' poor prognosis.
    Zhang K; Chen H; Wu G; Chen K; Yang H
    Med Oncol; 2014 Nov; 31(11):247. PubMed ID: 25260803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma.
    Chen KW; Yang HL; Lu J; Wang GL; Ji YM; Wu GZ; Zhu LF; Liu JY; Chen XQ; Gu YP
    J Neurooncol; 2011 Feb; 101(3):357-63. PubMed ID: 20549300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low expression of PHLPP1 in sacral chordoma and its association with poor prognosis.
    Chen H; Zhang K; Wu G; Song D; Chen K; Yang H
    Int J Clin Exp Pathol; 2015; 8(11):14741-8. PubMed ID: 26823799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of far upstream element-binding protein 1 correlates with c-Myc expression in sacral chordomas and is associated with tumor progression and poor prognosis.
    Wen H; Ma H; Li P; Zheng J; Yu Y; Lv G
    Biochem Biophys Res Commun; 2017 Sep; 491(4):1047-1054. PubMed ID: 28780352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence.
    Zhang K; Chen H; Zhang B; Sun J; Lu J; Chen K; Yang H
    Int J Clin Exp Pathol; 2015; 8(1):608-14. PubMed ID: 25755752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in sacral chordoma.
    Zhou M; Chen K; Yang H; Wang G; Lu J; Ji Y; Wu C; Chen C
    J Neurooncol; 2014 Jan; 116(1):77-82. PubMed ID: 24135846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-reactive protein as a prognostic factor in patients with chordoma of lumbar spine and sacrum--a single center pilot study.
    Hobusch GM; Bodner F; Walzer S; Marculescu R; Funovics PT; Sulzbacher I; Windhager R; Panotopoulos J
    World J Surg Oncol; 2016 Apr; 14():111. PubMed ID: 27091202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What Are the Conditional Survival and Functional Outcomes After Surgical Treatment of 115 Patients With Sacral Chordoma?
    Ji T; Guo W; Yang R; Tang X; Wang Y; Huang L
    Clin Orthop Relat Res; 2017 Mar; 475(3):620-630. PubMed ID: 26975382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of risk factors for recurrence after the resection of sacral chordoma combined with embolization.
    Yang H; Zhu L; Ebraheim NA; Liu X; Castillo S; Tang T; Liu J; Cui H
    Spine J; 2009 Dec; 9(12):972-80. PubMed ID: 19800296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence and survival factors analysis of 171 cases of sacral chordoma in a single institute.
    Yang Y; Niu X; Li Y; Liu W; Xu H
    Eur Spine J; 2017 Jul; 26(7):1910-1916. PubMed ID: 27942938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosome 3p loss of heterozygosity and reduced expression of H3K36me3 correlate with longer relapse-free survival in sacral conventional chordoma.
    Zhu GG; Ramirez D; Chen W; Lu C; Wang L; Frosina D; Jungbluth A; Ntiamoah P; Nafa K; Boland PJ; Hameed MR
    Hum Pathol; 2020 Oct; 104():73-83. PubMed ID: 32795465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression of survivin in sacral chordoma.
    Chen C; Yang HL; Chen KW; Wang GL; Lu J; Yuan Q; Gu YP; Luo ZP
    Med Oncol; 2013 Jun; 30(2):529. PubMed ID: 23504337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP1 is a novel independent prognostic factor for the poor prognosis of chordoma.
    Li Z; Lv T; Liu Y; Huang X; Qiu Z; Li J
    Cancer Biomark; 2016 Mar; 16(4):633-9. PubMed ID: 27002766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and sacral chordomas.
    Jäger D; Barth TFE; Brüderlein S; Scheuerle A; Rinner B; von Witzleben A; Lechel A; Meyer P; Mayer-Steinacker R; Baer AV; Schultheiss M; Wirtz CR; Möller P; Mellert K
    Sci Rep; 2017 May; 7(1):2032. PubMed ID: 28515451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients.
    Bergh P; Kindblom LG; Gunterberg B; Remotti F; Ryd W; Meis-Kindblom JM
    Cancer; 2000 May; 88(9):2122-34. PubMed ID: 10813725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chordoma: Immunohistochemical Analysis of Brachury.
    Sun HI; Guduk M; Gucyetmez B; Yapicier O; Pamir MN
    Turk Neurosurg; 2018; 28(2):174-178. PubMed ID: 28094431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis.
    Luo P; Wang X; Zhou J; Li L; Jing Z
    Hum Pathol; 2018 Apr; 74():129-134. PubMed ID: 29317233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chordoma and chondroid neoplasms of the spheno-occiput. An immunohistochemical study of 41 cases with prognostic and nosologic implications.
    Mitchell A; Scheithauer BW; Unni KK; Forsyth PJ; Wold LE; McGivney DJ
    Cancer; 1993 Nov; 72(10):2943-9. PubMed ID: 7693324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.